EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The CD70/CD27 Axis in Tyrosine Kinase Inhibitor-Treated Chronic Phase Chronic Myeloid Leukemia Cells Is Not an Achilles Heel

Jennifer Cassels, Mark E Drotar, Alyson MacNeil iD, Michael W Moles, Ya-Ching Hsieh, Cassie J Clarke iD, Eoghan Forde iD, Lorna Jackson, Moira A Elliott, Julie Jacobs, Piotr Zabrocki, Mhairi Copland iD und 3 weitere

Hematology Reports · 17.08.2026 · 18 (4) · 59

DOI: 10.3390/hematolrep18040059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematology Reports, online erschienen am 17.08.2026. Verfasst von Jennifer Cassels und 14 weiteren Autor:innen. Beteiligte Einrichtung: Paul O'Gorman Leukaemia Research Centre, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, 21 Shell…. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Howat Foundation, Friends of Paul O’Gorman and Beatson Cancer Charity.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Revolutionary small molecule, targeted, tyrosine kinase inhibitors (TKIs) in the clinic have engendered the perception that optimal treatment has already been established for diseases like chronic myeloid leukemia (CML). Addressing BCR::ABL1 oncokinase domain mutations in CML is unlikely to redress disease recrudescence owing to persistent leukemia stem cells (LSCs). Therefore, it is necessary to consider an alternative strategic approach: disrupting LSC interactions with the protective microenvironment and/or immune system. The interaction of the TNF-α superfamily member, CD27, with its upregulated ligand, CD70, initiates survival signaling specifically in CML cells when BCR::ABL1 is inhibited by TKIs and thus represents an attractive target. Previous studies modulating the expression of CD27 on LSCs in a mouse model of advanced phase CML were encouraging. In our study, we explored the CD70/CD27 axis as a therapeutic target in early-phase disease.

Methods

Primitive CD34+ cells from treatment-naïve chronic phase (CP) CML patients were drug-exposed in an in vitro co-culture system; combination drug treatments of the therapeutic anti-CD70 antibody and TKIs, nilotinib, were assessed in our CP CML murine model.

Results

The blockade of the CD70/CD27 axis in combination with TKIs did not result in greater LSC elimination than with nilotinib as a single agent in our CP CML models. Nonetheless, there was an observed reduction in CD70+ cells with combination treatment.

Conclusion

Further preclinical study of the antibody as an adjunct in CD70-expressing hematological malignancy is perhaps warranted.

Schlagwörter

Stichwörter der Autor:innen

Wntleukemia stem cellssignal blockade

Autor:innen und Institutionen

  • Paul O'Gorman Leukaemia Research Centre, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, 21 Shelley Road, Glasgow G12 0ZD, UK.
  • Centre for Healthcare Randomised Trials (CHaRT), Aberdeen Centre for Evaluation, Health Sciences Building, Foresterhill, Aberdeen AB25 2ZD, UK.
  • Scotland Institute, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Switchback Road, Glasgow G61 1BD, UK.
  • Medical Research Council Centre for Inflammation Research, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK.
  • Scottish National Blood Transfusion Service, Jack Copland Centre, Currie, Edinburgh EH14 4BE, UK.
  • argenx BV, Industriepark Zwijnaarde 7, Zwijnaarde, 9052 Ghent, Belgium.

ORCID-Profile: Alyson MacNeil, Cassie J Clarke, Eoghan Forde, Mhairi Copland, Helen Wheadon, Alison M Michie, Heather G Jørgensen

Förderung

  • Cancer Research UK
  • Howat Foundation
  • Friends of Paul O’Gorman and Beatson Cancer Charity
  • MRC DTP in Precision Medicine, University of Glasgow

Zitieren

APA

Cassels, J., Drotar, M. E., MacNeil, A., Moles, M. W., Hsieh, Y. C., Clarke, C. J., Forde, E., Jackson, L., Elliott, M. A., Jacobs, J., Zabrocki, P., Copland, M., Wheadon, H., Michie, A. M., & Jørgensen, H. G. (2026). The CD70/CD27 Axis in Tyrosine Kinase Inhibitor-Treated Chronic Phase Chronic Myeloid Leukemia Cells Is Not an Achilles Heel. Hematology Reports, 18(4), 59. https://doi.org/10.3390/hematolrep18040059

Vancouver

Cassels J, Drotar ME, MacNeil A, Moles MW, Hsieh YC, Clarke CJ, et al. The CD70/CD27 Axis in Tyrosine Kinase Inhibitor-Treated Chronic Phase Chronic Myeloid Leukemia Cells Is Not an Achilles Heel. Hematology Reports. 2026;18(4):59. doi:10.3390/hematolrep18040059

BibTeX
@article{Cassels2026,
  author = {Cassels, Jennifer and Drotar, Mark E and MacNeil, Alyson and Moles, Michael W and Hsieh, Ya-Ching and Clarke, Cassie J and Forde, Eoghan and Jackson, Lorna and Elliott, Moira A and Jacobs, Julie and Zabrocki, Piotr and Copland, Mhairi and Wheadon, Helen and Michie, Alison M and Jørgensen, Heather G},
  title = {The CD70/CD27 Axis in Tyrosine Kinase Inhibitor-Treated Chronic Phase Chronic Myeloid Leukemia Cells Is Not an Achilles Heel},
  journal = {Hematology Reports},
  year = {2026},
  volume = {18},
  number = {4},
  pages = {59},
  doi = {10.3390/hematolrep18040059}
}
Kostenlos starten →